Journal
NEUROPHARMACOLOGY
Volume 72, Issue -, Pages 291-300Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuropharm.2013.04.008
Keywords
Glucagon-like peptide-1; Type 2 diabetes; Amyloid beta; Tau; Inflammatory markers; Hippocampus; Wistar rats
Categories
Funding
- Council of Scientific and Industrial Research (CSIR), New Delhi, India
- NHMRC [570398]
Ask authors/readers for more resources
Type 2 diabetes (T2D) is one of the major risk factors associated with Alzheimer's disease (AD). Recent studies have found similarities in molecular mechanisms that underlie the respective degenerative developments in the two diseases. Pharmacological agents, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase the level of glucagon-like peptide-1 (GLP-1) and ameliorate T2D, have become valuable candidates as disease modifying agents in the treatment of AD. In addition, endogenous GLP-1 levels decrease amyloid beta (A beta) peptide and tau phosphorylation in AD. The present study examines the efficacy of Saxagliptin, a DPP-4 inhibitor in a streptozotocin (STZ) induced rat model of AD. Three months following induction of AD by intracerebral administration of streptozotocin, animals were orally administered Saxagliptin (0.25, 0.5 and 1 mg/kg) for 60 days. The effect of the DPP-4 inhibitor on hippocampal GLP-1 levels, A beta burden, tau phosphorylation, inflammatory markers and memory retention were evaluated. The results reveal an attenuation of A beta, tau phosphorylation and inflammatory markers and an improvement in hippocampal GLP-1 and memory retention following treatment. This remarkable therapeutic effect of Saxagliptin mediated through DPP-4 inhibition demonstrates a unique mechanism for A beta and tau clearance by increasing GLP-1 levels and reverses the behavioural deficits and pathology observed in AD. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available